Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

Item
http://www.wikidata.org/entity/Q33374067

Addition of rituximab to standard therapy improves response rate and progression-free survival in relapsed or refractory thrombotic thrombocytopenic purpura and autoimmune haemolytic anaemia.

Item
http://www.wikidata.org/entity/Q33374067
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@ast
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@en
type
label
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@ast
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@en
prefLabel
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@ast
Addition of rituximab to stand ...... autoimmune haemolytic anaemia.
@en
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921
P356
P1433
P1476
Addition of rituximab to stand ...... autoimmune haemolytic anaemia
@en
P2093
P304
P31
P356
P433
P478
P50
P577
P698
P921